EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

Saba Musleh Ud Din, Spencer G Streit iD, Bao Tran Huynh, Caroline Hana iD, Anna-Ninny Abraham, Atif Hussein

International Journal of Molecular Sciences · 08.02.2024 · 25 (4) · 2060

DOI: 10.3390/ijms25042060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.02.2024. Verfasst von Saba Musleh Ud Din und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the realm of cancer therapeutics, targeting the hypoxia-inducible factor (HIF) pathway has emerged as a promising strategy. This study delves into the intricate web of HIF-associated mechanisms, exploring avenues for future anticancer therapies. Framing the investigation within the broader context of cancer progression and hypoxia response, this article aims to decipher the pivotal role played by HIF in regulating genes influencing angiogenesis, cell proliferation, and glucose metabolism. Employing diverse approaches such as HIF inhibitors, anti-angiogenic therapies, and hypoxia-activated prodrugs, the research methodologically intervenes at different nodes of the HIF pathway. Findings showcase the efficacy of agents like EZN-2968, Minnelide, and Acriflavine in modulating HIF-1α protein synthesis and destabilizing HIF-1, providing preliminary proof of HIF-1α mRNA modulation and antitumor activity. However, challenges, including toxicity, necessitate continued exploration and development, as exemplified by ongoing clinical trials. This article concludes by emphasizing the potential of targeted HIF therapies in disrupting cancer-related signaling pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansVon Hippel-Lindau Tumor Suppressor ProteinVascular Endothelial Growth Factor AHypoxiaHypoxia-Inducible Factor 1, alpha Subunit

Stichwörter der Autor:innen

cancerepithelial–mesenchymal transition (EMT)hypoxia-inducible factors (HIFs)signal transduction pathwaystranscription factorstumor immune escapetumor microenvironmentvascular endothelial growth factor (VEGF)von Hippel–Lindau syndrome (VHL)

Substanzen

Von Hippel-Lindau Tumor Suppressor ProteinVascular Endothelial Growth Factor AHypoxia-Inducible Factor 1, alpha Subunit

Autor:innen und Institutionen

  • Department of Internal Medicine, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.
  • Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.
  • Department of Pharmacy, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.

ORCID-Profile: Spencer G Streit, Caroline Hana

Zitieren

APA

Musleh Ud Din, S., Streit, S. G., Huynh, B. T., Hana, C., Abraham, A. N., & Hussein, A. (2024). Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer. International Journal of Molecular Sciences, 25(4), 2060. https://doi.org/10.3390/ijms25042060

Vancouver

Musleh Ud Din S, Streit SG, Huynh BT, Hana C, Abraham AN, Hussein A. Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer. International Journal of Molecular Sciences. 2024;25(4):2060. doi:10.3390/ijms25042060

BibTeX
@article{MuslehUdDin2024,
  author = {Musleh Ud Din, Saba and Streit, Spencer G and Huynh, Bao Tran and Hana, Caroline and Abraham, Anna-Ninny and Hussein, Atif},
  title = {Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {4},
  pages = {2060},
  doi = {10.3390/ijms25042060}
}
Kostenlos starten →